Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Media News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Investor Update - October 18, 2023 Category: Pharmaceuticals Source Type: news
FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC
The approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
J & J lung cancer drug combo had superior progression-free survival in study
(Source: Reuters: Health)
Source: Reuters: Health - October 17, 2023 Category: Consumer Health News Source Type: news
Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer
Mark G. Kris, MD, discusses neoadjuvant therapy for patients with locally advanced lung cancers.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
